Abstract: The need for a durable bottom dispensing package which is easy to dispense from, while having sufficient elasticity to return back to its original shape after dispensing, while also being easy to clean, and having reduced or no leakage during use, is met by making the container of the bottom dispensing package from an elastomer, and providing the interior surface of the container with at least one circumferentially oriented groove.

Abstract: The need for an improved durable bottom dispensing package that incorporates elastomer materials within the container, while enabling users to accurately dose both small and large quantities of the composition contained within, is met by forming the container of the bottom-dispensing package such that the container wall has a wider portion, such that at least part of the exterior surface of the container has a convex shape, and a narrow portion, such that at least part of the exterior surface of the container wall has a concave shape which is narrower than the adjacent parts of the container.

Abstract: The need for a bottom dispensing packaging that can more easily reflate to its original shape, even when used with containers which are more flexible, is met when the container is provided with a one-way vent which allows the ingress of air into the container while preventing the egress of air from the container.

Abstract: The need for a durable environmentally-friendly dispensing package which is easy to dispense from, while having sufficient elasticity to return back to its original shape after dispensing, while also being easy to clean, and having reduced or no leakage during use, is met by making the container of a reversibly squeezable material and by providing rigid top and bottom rings fixedly attached to the squeezable material.

Abstract: A bottom dispensing package for a liquid composition includes a resiliently squeezable container for housing the liquid composition; and a base operably connected to the container, wherein the base comprises an orifice. The body of the base is at least partially made from an elastomer. The elastomer used in the base has a Shore A (Type A) hardness of from about 0 to about 80, and the shore A hardness is measured using the method described in ISO 868:2003.

Abstract: A lightweight end cap for an ammunition cartridge, said end cap having a central axis along its axial length, with a first radius; wherein said end cap further comprises a swept volume rebate; having a second radius less than the first radius, wherein the second radius is at least 10% smaller than the first radius, and wherein the swept volume rebate extends along at least 10% of the axial length of said end cap, wherein the end cap further comprises an extractor groove suitable for receiving an ejection mechanism.

Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Abstract: According to the present invention, there is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions, an ammunition cartridge locator aide, said locator aid locates in an ejector groove of a received cartridge and, the wire ammunition belt link further comprising a support surface suitable for retaining the first and/or second ammunition cartridge.

Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Abstract: The invention relates to a method of improved ammunition production, particularly to a metal matrix composite(MMC) end cap, suitable for forming a cartridge case, said end cap comprising an admixture of a metal powder, a binder matrix material, wherein said admixture has been caused to solidify in the shape of said end cap.

Abstract: The invention relates to a method of improved ammunition production, more specifically to a cellular structure end cap, suitable for an ammunition round, said end cap comprising a porous 3D spatial structure in the shape of said end cap, wherein in said porous 3D spatial structure comprises a surface skin.

Abstract: A lightweight end cap for an ammunition cartridge, said end cap having a central axis along its axial length, with a first radius; wherein said end cap further comprises a swept volume rebate; having a second radius less than the first radius, wherein the second radius is at least 10% smaller than the first radius, and wherein the swept volume rebate extends along at least 10% of the axial length of said end cap, wherein the end cap further comprises an extractor groove suitable for receiving an ejection mechanism.

Abstract: There is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions; and an ammunition cartridge locator aide, said aide locates in an ejector groove of a received cartridge.

Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Abstract: Provided herein are methods, assays and devices for the detection and diagnosis of autoimmune diseases, including systemic lupus erythematosus. The methods, assays and devices provided herein analyzes binding patterns of peripheral-blood antibodies on peptide array that correlates well with current systemic lupus erythematosus clinical assessment standards.

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract: There is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions; and an ammunition cartridge locator aide, said aide locates in an ejector groove of a received cartridge.

Abstract: According to the present invention, there is provided an ammunition belt link comprising, a sprung wire, said sprung wire arranged to form a first receiving portion suitable for retaining a first ammunition cartridge, a second receiving portion suitable for retaining a second ammunition cartridge, a spacer between said first receiving and second receiving portions, an ammunition cartridge locator aide, said locator aid locates in an ejector groove of a received cartridge and, the wire ammunition belt link further comprising a support surface suitable for retaining the first and/or second ammunition cartridge.

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Abstract: Microfluidic devices and methods of quantifying fatty acids and/or specialized pro-resolving mediators and/or fatty acid metabolites present in a fluid sample on a microfluidic device are described herein. The methods include extracting fatty acid esters containing fatty acids from the fluid sample, combining the extracted fatty acid esters with a hydrolyzing agent to cleave the fatty acids from the extracted fatty acid esters and form free fatty acids, and quantifying the free fatty acids by performing a bioassay specific to the free fatty acids. Microfluidic devices and methods of quantifying fatty acid metabolites present in a fluid sample on a microfluidic device are also described herein.